INmune Bio Inc
INMB
Get informed when a big investor buys or sells
+ FollowMarket Cap$51.58M
Close$
$0.83
59.9% downside
Current Fair Value
59.9% downsideOvervalued by 59.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $51.58 Million |
|---|---|
| Enterprise Value | $31.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.86 |
| Beta | 0.98 |
| Outstanding Shares | 26,585,258 |
Return
| Return on Equity | -211.99% |
|---|---|
| Return on Assets | -161.13% |
| Return on Invested Capital | -65.50% |
Valuation & Multiples
| P/E Ratio | -1.15 |
|---|---|
| PEG | 2.58 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.37 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
$1.11 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$1.16 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7098▲ 1.24% |
|---|---|
| Total Calls | 44,100▼ 47.87% |
| Total Puts | 31,300▼ 46.95% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.23%▲ 1.10% |
|---|---|
| Total Invested | $6.09M▼ 23.28% |
| Investors Holding | 86▲ 9.00% |
ESG Score
No data